PTC Therapeutics exec. VP Boulding sells $408,612 in stock
#PTC Therapeutics #Mark Elliott Boulding #Rule 10b5-1 #NASDAQ #Sephience #PKU #Translarna #Barclays #Goldman Sachs #Insider Sale
📌 Key Takeaways
- Boulding sold 5,894 shares of PTCT common stock on 17–18 Feb 2026.
- Total proceeds from the sale were $408,612.
- Transactions were conducted under a pre‑arranged Rule 10b5‑1 plan established on 4 Dec 2024.
- Boulding also exercised options to acquire 2,813 shares on the same day.
- PTC reported Q4 revenue of $92.5 million for its Sephience drug.
- The company received Japanese approval for its PKU treatment, Sephience.
- PTC withdrew its NDA for Translarna after FDA guidance.
- Barclays initiated coverage with an Overweight rating.
- Goldman Sachs raised its price target to $55 but retained a Sell rating.
📖 Full Retelling
🏷️ Themes
Insider Trading, Regulatory Compliance, Pharmaceutical Development, Analyst Coverage
Entity Intersection Graph
No entity connections available yet for this article.
Deep Analysis
Why It Matters
The sale of over 5,800 shares by PTC Therapeutics’ Executive Vice President reflects a routine liquidity move under a pre‑arranged trading plan, not a sign of insider concern. However, the transaction occurs amid strong quarterly earnings and a new product approval, which could influence investor perception of the company’s growth prospects.
What Happens Next
Investors will watch for the company’s next quarterly report to see if the PKU treatment continues to drive revenue growth and whether the withdrawal of the Translarna NDA affects pipeline momentum. Analysts may adjust price targets as new data on drug development and market expansion emerges.